My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Study Name
  My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
ClinicalTrials.gov Identifier (if applicable)
  NCT02091141
Study Center
Institution Name
  Science 37 Inc.
Institution Address
  5875 Green Valley Circle, Suite 100
City
  Culver City
State
  California
Zip Code
  90230
Phone
  (720) 207-8363
Website
  https://www.science37.com/
Study Contacts
Principal Investigator
  David Chan, MD
P.I. Phone
  (213) 529-0657
P.I. Email
  mypathway@science37.com
Study Coordinator
  Jade Yen
Study Coordinator Phone
  (213) 529-0657
Study Coordinator Email
  jade@science37.com
OVERVIEW – in layman’s terms (150 words max)
  This open-label study is looking at targeted therapies in patients with advanced cancer for whom there is no available, beneficial treatment.
Enrollment
  This study is currently recruiting participants.
Study Start Date
  04/01/2014
Estimated Completion Date
  08/01/2019
Purpose of the Study – in Layman’s Terms (use the “+” to add more list items)
 
  • This research study focuses on targeted therapies for people diagnosed with metastatic cancer.
  • Targeted therapy is a newer type of cancer treatment based on specifically targeting genetic mutations (abnormalities) found in a tumor.
  • This research study explores multiple investigational medications and their effect on specific mutations found in tumors.
  • The goal of this research study is to find out how well the investigational medications may work to treat metastatic cancer with known mutations.
Inclusion Criteria – Patients Must:
 
  • At least 18 years of age or older.
  • Live in the state of California.
  • Currently diagnosed with advanced or metastatic cancer.
  • Received prior anti-cancer treatment.
REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms
 
  • Molecular/genetic testing

 

Pin It on Pinterest